Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

Local companies are developing technologies that they hope could replace a painful poke with something that feels more like ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Natco Pharma and Dr. Reddy's Laboratories are eyeing blockbuster drug–Novo Nordisk’s breakout star Semaglutide, sold under ...

The U.S. drugmaker spent nearly $2 billion in 2023 to acquire Versanis Bio's bimagrumab, which prevents the activity of a ...

Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...